I. Schmidt-Wolf

发表

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

David McDermott, R. Figlin, R. Motzer, 2007, The New England journal of medicine.

A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA.

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation

I. Schmidt-Wolf, P. Bigey, F. Schakowski, 2004, Genetic vaccines and therapy.

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

R. Fimmers, H. Reichmann, C. Schaller, 2009, Journal of Neuro-Oncology.

Activated γδ T cells express the natural cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cells

G. Feldmann, J. Nattermann, S. Frank, 2006 .

Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells

C. Gross, I. Schmidt-Wolf, J. Ellwart, 2003, Cell stress & chaperones.

Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.

I. Weissman, D. Huhn, I. Schmidt-Wolf, 1993, Experimental hematology.

Neutropenic enterocolitis in adults: systematic analysis of evidence quality

T. Sauerbruch, A. Glasmacher, C. Ziske, 2005, European journal of haematology.

Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study

R. Fimmers, T. Klockgether, M. Deckert, 2001, Journal of neurology, neurosurgery, and psychiatry.

Cellular Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation: Experimental Strategies and Clinical Experiences

T. Bieber, A. Glasmacher, I. Schmidt-Wolf, 2003, Leukemia & lymphoma.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.

E. Thiel, W. Hiddemann, H. Döhner, 2014, Blood.

Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.

S. Chen, C. Rooney, I. Schmidt-Wolf, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors.

Y. Ko, S. Stier, I. Schmidt-Wolf, 2007, International journal of radiation oncology, biology, physics.

High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis.

C. Mayr, B. Djulbegovic, A. Glasmacher, 2003, Haematologica.

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.

B. Djulbegovic, S. Engelhart, A. Glasmacher, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of patients with acute myeloid leukemia and pulmonary infiltrates requiring invasive mechanical ventilation-a retrospective analysis.

T. Sauerbruch, A. Glasmacher, C. Rabe, 2004, Journal of critical care.

Activation of Invariant NK T Cells in Periodontitis Lesions

Justus M. Kebschull, P. Papapanou, P. Hoffmann, 2013, The Journal of Immunology.

Long-Term Survival of a Patient with Small Cell Lung Cancer after Nine Lines of Chemotherapy and Radiation

T. Sauerbruch, O. Gressner, N. Friedrichs, 2008, Oncology Research and Treatment.

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

E. Giné, M. Czuczman, J. Winter, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

A. Krämer, A. Ho, A. Benner, 2011 .

Effects of adenoviral wild-type p53 gene transfer in p53 -mutated lymphoma cells

C. Ziske, K. Brand, I. Schmidt-Wolf, 2001, Cancer Gene Therapy.

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

I. Schmidt-Wolf, U. Germing, A. Engert, 2004, Haematologica.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H. Goldschmidt, P. Sonneveld, E. Vellenga, 2008, Haematologica.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Martin C. Müller, N. Schmitz, J. Hasford, 2015, Blood.

High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma

C. Rabe, I. Schmidt-Wolf, U. Mey, 2007, German medical science : GMS e-journal.

Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

A. Glasmacher, A. Ho, C. Rabe, 2006, Cancer investigation.

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

I. Weissman, I. Schmidt-Wolf, H. Kiem, 1991, The Journal of experimental medicine.

Generation of dendritic cell-based vaccines for cancer therapy

T. Bieber, I. Schmidt-Wolf, A. Märten, 2002, British Journal of Cancer.

Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2003, Gut.

Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology

T. Sauerbruch, A. Glasmacher, C. Ziske, 2002, British journal of haematology.

Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.

T. Sauerbruch, V. Schmitz, C. Ziske, 2003, Cancer research.

U. Jaehde, I. Schmidt-Wolf, M. Schmid, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Lymphokine-activated killer cell activity after cryopreservation.

I. Schmidt-Wolf, R. Negrin, N. Chao, 1989, Journal of immunological methods.

Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells.

I. Weissman, I. Schmidt-Wolf, R. Negrin, 1995, Blood.

A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy.

B. Sikic, I. Schmidt-Wolf, N. Chao, 1991, Blood.

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

A. Glasmacher, S. Frank, P. Brossart, 2010, Cancer Immunology, Immunotherapy.

Coculture with dendritic cells promotes proliferation but not cytotoxic activity of γ/δ T cells

I. Schmidt-Wolf, M. Gorschlueter, A. Märten, 2005 .

Characterization of Primary Renal Carcinoma Cultures

M. Büchler, I. Schmidt-Wolf, Jan Schmidt, 2007, Urologia Internationalis.

Requirements for Adeno-Associated Virus-Derived Non-Viral Vectors to Achieve Stable and Site-Specific Integration of Plasmid DNA in Liver Carcinoma Cells

V. Schmitz, W. Caselmann, C. Rabe, 2003, Digestion.

Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2008 .

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2008 .

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Cytokines and gene therapy.

I. Schmidt-Wolf, I. Schmidt-Wolf, G. Schmidt‐Wolf, 1995, Immunology today.

Cytokines and clinical gene therapy

I. Schmidt-Wolf, G. Schmidt‐Wolf, 1995, European journal of immunology.

Telomerase‐specific T‐cells kill pancreatic tumor cells in vitro and in vivo

M. Büchler, I. Schmidt-Wolf, Jan Schmidt, 2006, Cancer.

Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2002, Cancer Immunology, Immunotherapy.

Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2000, International Journal of Colorectal Disease.

Increase of the Immunostimulatory Effect of Dendritic Cells by Pulsing With CA 19-9 Protein

D. Huhn, T. Sauerbruch, C. Ziske, 2000, Journal of immunotherapy.

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

P. Albers, T. Sauerbruch, C. Ziske, 2002, Cancer Immunology, Immunotherapy.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.

Yang Li, Ke Huang, I. Schmidt-Wolf, 2010, Anticancer research.

Interaction of psychological factors and the effect of epoetin alfa treatment in cancer patients on hemoglobin and fatigue

T. Sauerbruch, A. Glasmacher, I. Schmidt-Wolf, 2007, Supportive Care in Cancer.

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.

R. Fimmers, H. Reichmann, H. Urbach, 2010, Neuro-oncology.

Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells

I. Schmidt-Wolf, B. Schöttker, 2011, German medical science : GMS e-journal.

Effect of Oxygen Levels on the Physiology of Dendritic Cells: Implications for Adoptive Cell Therapy

I. Schmidt-Wolf, M. Larsson, D. Messmer, 2011, Molecular medicine.

Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell Hybrids

T. Sauerbruch, V. Schmitz, C. Ziske, 2009, Pancreas.

Morphine Reciprocally Regulates IL-10 and IL-12 Production by Monocyte-Derived Human Dendritic Cells and Enhances T Cell Activation

I. Schmidt-Wolf, P. Singhal, D. Messmer, 2006, Molecular medicine.

Cross-sectional increase of adherence to multidisciplinary tumor board decisions

T. Manser, I. Schmidt-Wolf, N. Ernstmann, 2018, BMC Cancer.

DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis

A. Glasmacher, C. Rabe, I. Schmidt-Wolf, 2006, Leukemia & lymphoma.

Activated T cells and cytokine-induced CD3+CD56+ killer cells

I. Schmidt-Wolf, R. Negrin, G. Schmidt‐Wolf, 1997, Annals of Hematology.

In vitro and in vivo activity of murine lymphokine‐activated killer cells after cryopreservation

I. Schmidt-Wolf, R. Negrin, N. Chao, 1992, Transfusion.

Pharmacokinetics and efficacy of pegfilgrastim as hematopoietic support for dose-dense every-2-week chemo-immunotherapy with R-CHOP as first-line therapy in elderly patients with diffuse large B cell lymphoma.

A. Glasmacher, C. Ziske, I. Schmidt-Wolf, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer

M. Stauch, H. Oettle, H. Riess, 2005 .

Anti-tumoral capabilities of effector cells after IFN-α or CpG-motif treatment of cocultured dendritic cells

S. Frank, I. Schmidt-Wolf, M. Gorschlueter, 2006, Archivum Immunologiae et Therapiae Experimentalis.

Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection

D. Huhn, W. Caselmann, K. Brand, 2000, Cancer Gene Therapy.

Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma

R. Parwaresch, A. Ho, A. Benner, 2004, European journal of haematology.

Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57BL/6 pancreatic tumor model.

T. Sauerbruch, V. Schmitz, C. Ziske, 2009, Pancreas.

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

K. Döhner, R. Schlenk, H. Döhner, 2008 .

Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma

T. Hielscher, A. Krämer, A. Ho, 2012, American journal of hematology.

T-cell subsets and suppressor cells in human bone marrow.

P. Greenberg, I. Schmidt-Wolf, S. Strober, 1992, Blood.

Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.

H. Goldschmidt, A. Glasmacher, I. Schmidt-Wolf, 2006, Cancer genetics and cytogenetics.

Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma

R. Fimmers, H. Reichmann, K. Fliessbach, 2020, Neurology.

State-of-the-art classification and multimodality treatment of malignant thymoma.

H. Müller-Hermelink, J. Rockstroh, I. Schmidt-Wolf, 2012, Cancer treatment reviews.

Malignant thymoma: current status of classification and multimodality treatment

D. Huhn, H. Müller-Hermelink, J. Rockstroh, 2003, Annals of Hematology.

Absent immunoglobulins in HIV-related Burkitt lymphoma/leukaemia

A. Shimomura, R. Büttner, I. Schmidt-Wolf, 2008, Annals of Hematology.

Sequential Hodgkin’s and non-Hodgkin’s lymphoma in non-immunocompromised patients

I. Schmidt-Wolf, J. Kirfel, I. Gütgemann, 2013, Annals of Hematology.

Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC

C. Ziske, I. Schmidt-Wolf, P. Buttgereit, 2004 .

Genetic Vaccines and Therapy

C. Ziske, I. Schmidt-Wolf, P. Buttgereit, 2004 .

Endoscopy in patients with acute leukaemia after intensive chemotherapy.

T. Sauerbruch, V. Schmitz, I. Schmidt-Wolf, 2008, Leukemia research.

Primary small cell carcinoma of the esophagus: patient data metaanalysis and review of the literature

C. Ziske, I. Schmidt-Wolf, Saineb Al Mansoor, 2013, German medical science : GMS e-journal.

Bone marrow and clinical gene therapy.

I. Schmidt-Wolf, G. Schmidt‐Wolf, 1995, Journal of hematotherapy.

Human cancer and gene therapy

I. Schmidt-Wolf, G. Schmidt‐Wolf, G. Schmidt-Wolf, 1994, Annals of Hematology.

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.

R. Fimmers, P. Albers, I. Schmidt-Wolf, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural Killer T Cells Subsets in Cancer, Functional Defects in Prostate Cancer and Implications for Immunotherapy

I. Schmidt-Wolf, Michael D. Nowak, 2011, Cancers.

T guided pancreatic carcinoma mouse model activating lipopeptide MALP-2 in an ultrasound Tumour suppression induced by the macrophage

Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2003 .

Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo.

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2006, International immunology.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3ζ-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells

H. Schild, T. Sauerbruch, S. Frank, 2005, Gut.

Increase of the stimulatory effect of dendritic cells by pulsing with apoptotic bodies transfected with the MHC class II gene.

I. Schmidt-Wolf, A. Märten, S. Renoth, 2002, Molecular immunology.

Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells

I. Schmidt-Wolf, H. Abken, C. Schlimper, 2012, Clinical & developmental immunology.

Cytokine-induced killer cells are type II natural killer T cells

S. Frank, I. Schmidt-Wolf, J. Strehl, 2007, German medical science : GMS e-journal.

SAP and SLAM expression in anti‐CD3 activated lymphocytes correlates with cytotoxic activity

S. Frank, I. Schmidt-Wolf, Jan Schmidt, 2005, Immunology and cell biology.

Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer

C. Ziske, I. Schmidt-Wolf, S. Nagaraj, 2004, Genetic vaccines and therapy.

Interactions Between Dendritic Cells and Cytokine-Induced Killer Cells Lead to an Activation of Both Populations

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2001, Journal of immunotherapy.

Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9.

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Propagation of large numbers of cells of a human mixed‐lineage T‐lymphoid/myeloid

D. Huhn, I. Schmidt-Wolf, C. Scheffold, 1995, British journal of haematology.

Long‐term follow‐up of Cladribine, high‐dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review

A. Glasmacher, P. Brossart, I. Schmidt-Wolf, 2020, European journal of haematology.

Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)

L. Bullinger, K. Döhner, R. Schlenk, 2015 .

Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Y. Ko, I. Schmidt-Wolf, U. Kaiser, 2016, Cancer investigation.

Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.

P. Albers, T. Sauerbruch, I. Schmidt-Wolf, 2003, Human gene therapy.

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2010 .

The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma

K. Fliessbach, T. Klockgether, H. Kölsch, 2004, British Journal of Cancer.

Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.

T. Sauerbruch, U. Spengler, I. Schmidt-Wolf, 1999, Hybridoma.

[Acute central nervous symptoms in oncologic patients].

H. Urbach, U. Schlegel, I. Schmidt-Wolf, 2005, Der Internist.

Increased Sensitivity of Myeloid Leukemia Cell Lines: Potential of Lovastatin as Bone-Marrow-Purging Agent

D. Huhn, A. Glasmacher, I. Schmidt-Wolf, 2001, Acta Haematologica.

Immunomodulatory gene therapy for haematological malignancies

I. Schmidt-Wolf, G. Schmidt‐Wolf, 2002, British journal of haematology.

Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2001, Cancer Gene Therapy.

Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging.

M. Cleary, I. Schmidt-Wolf, H. Kiem, 1991, Blood.

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Gastrointestinal Tumors

I. Schmidt-Wolf, M. Gonzalez-Carmona, A. Vogt, 2014, Journal of immunology research.

AML versus ICU: outcome of septic AML patients in an intensive care setting

P. Brossart, I. Schmidt-Wolf, P. Walger, 2015, Journal of Cancer Research and Clinical Oncology.

Invasive fungal infections in neutropenic enterocolitis: A systematic analysis of pathogens, incidence, treatment and mortality in adult patients

A. Glasmacher, V. Schmitz, C. Rabe, 2006, BMC infectious diseases.

Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2.

I. Schmidt-Wolf, M. Varvenne, D. Flieger, 2007, Cellular immunology.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Peter Neuhaus, Jan Langrehr, Karsten Ridwelski, 2007, JAMA.

Cancer and gene therapy

I. Schmidt-Wolf, G. Schmidt‐Wolf, G. Schmidt-Wolf, 1996, Annals of Hematology.

Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?

I. Schmidt-Wolf, H. Abken, S. Thanendrarajan, 2011, Leukemia research.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients wi

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

L. Bullinger, K. Döhner, R. Schlenk, 2018, Leukemia.

Littoral cell angioma as a rare cause of splenomegaly

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2001, Annals of Hematology.

Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.

T. Sauerbruch, C. Ziske, N. Abraham, 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Non-viral and hybrid vectors in human gene therapy: an update.

I. Schmidt-Wolf, G. Schmidt‐Wolf, G. Schmidt-Wolf, 2003, Trends in molecular medicine.

Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment

M. Deckert, U. Schlegel, I. Schmidt-Wolf, 2000, Journal of the Neurological Sciences.

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group

M. Pfreundschuh, R. Möhle, J. Finke, 2017, Leukemia.

Treatment options of AIDS-related lymphoma

D. Huhn, J. Rockstroh, U. Schlegel, 2003, Expert opinion on pharmacotherapy.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2015, Haematologica.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

D. Hose, H. Goldschmidt, A. Jauch, 2012, Blood.

Hairy cell leukemia: short review, today's recommendations and outlook

I. Schmidt-Wolf, G. Schmidt‐Wolf, U. Mey, 2014, Blood Cancer Journal.

Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

R. Fimmers, V. Diehl, H. Reichmann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib in patients with refractory or recurrent multiple myeloma

D. Hose, H. Goldschmidt, I. Schmidt-Wolf, 2013, Hematological oncology.

Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression

I. Schmidt-Wolf, H. Illges, H. Low, 2012, International Journal of Hematology.

Autologous and Allogeneic Bone Marrow Transplantation After Identical High-Dose Chemo-Radiotherapy in Children with Relapsed ALL

W. Siegert, G. Henze, I. Schmidt-Wolf, 1994 .

CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: A retrospective study

A. Glasmacher, I. Schmidt-Wolf, M. Gorschlueter, 2007, Leukemia & lymphoma.

Advances in the treatment of hairy-cell leukaemia.

A. Glasmacher, C. Ziske, I. Schmidt-Wolf, 2003, The Lancet. Oncology.

Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma.

K. Fliessbach, H. Urbach, T. Klockgether, 2003, Archives of neurology.

Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.

T. Sauerbruch, I. Schmidt-Wolf, D. Flieger, 2000, Cellular immunology.

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

H. Goldschmidt, P. Sonneveld, A. Glasmacher, 2003, Annals of Hematology.

Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells.

G. Feldmann, J. Nattermann, S. Frank, 2006, Clinical and experimental immunology.

High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

K. Döhner, R. Schlenk, H. Döhner, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene therapy for hematological malignancies

I. Schmidt-Wolf, G. Schmidt‐Wolf, 2003, Clinical and Experimental Medicine.

A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

H. Goldschmidt, A. Glasmacher, I. Schmidt-Wolf, 2006, British journal of haematology.

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy

K. Döhner, R. Schlenk, H. Döhner, 2016, Haematologica.

Transcriptional Profiling of the Nuclear Factor-&kgr;B Pathway Identifies a Subgroup of Primary Lymphoma of the Central Nervous System With Low BCL10 Expression

G. Reifenberger, R. Siebert, J. Martín-Subero, 2007, Journal of neuropathology and experimental neurology.

FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up

H. Urbach, J. Bucerius, U. Schlegel, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Rituximab maintenance improves survival in male patients with diffuse large B‐cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

A. Krämer, A. Ho, A. Benner, 2015, British journal of haematology.

Telomerase-pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma

P. Albers, H. Schild, T. Sauerbruch, 2006, German medical science : GMS e-journal.

Dendritic cell, the immunotherapeutic cell for cancer.

C. Ziske, I. Schmidt-Wolf, S. Nagaraj, 2004, The Indian journal of medical research.

5. Report on Workshop: Primary CNS Lymphoma

E. Thiel, I. Schmidt-Wolf, A. Korfel, 2001, Annals of Hematology.

Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care

Y. Ko, W. Kuhn, U. Jaehde, 2010, Supportive Care in Cancer.

Transfection of human monocyte‐derived dendritic cells with CpG oligonucleotides

C. Ziske, I. Schmidt-Wolf, M. Gorschlueter, 2005, Immunology and cell biology.

Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application

Ulrich Jaehde, U. Jaehde, I. Schmidt-Wolf, 2017, Scientia pharmaceutica.

Neuropsychological outcome after chemotherapy for primary CNS lymphoma

K. Fliessbach, H. Urbach, T. Klockgether, 2005, Neurology.

Pancreas Carcinoma Antigen Fused to Invariant Chain Elicits T-Cell Response and Tumor Growth Inhibition

S. Frank, C. Ziske, I. Schmidt-Wolf, 2008, Pancreas.

Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer

C. Ziske, I. Schmidt-Wolf, S. Nagaraj, 2004, Genetic vaccines and therapy.

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

C. Bokemeyer, R. Schirren, W. Berdel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

E. Buss, H. Serve, I. Schmidt-Wolf, 2012 .

Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide

M. Sanda, S. Balk, I. Schmidt-Wolf, 2010, PloS one.

Minimal size MIDGE vectors improve transgene expression in vivo.

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2007, In vivo.

Diffuse pulmonary alveolar hemorrhage after allogeneic bone marow transplantation

D. Huhn, W. Siegert, I. Schmidt-Wolf, 1993, Annals of Hematology.

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

Michael Reber, C. Ziske, I. Schmidt-Wolf, 2007, Supportive Care in Cancer.

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield

H. Goldschmidt, P. Sonneveld, A. Glasmacher, 2007, Leukemia.

Gene therapy of lymphoma.

I. Schmidt-Wolf, P. Buttgereit, 2002, Journal of hematotherapy & stem cell research.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

H. Goldschmidt, A. Glasmacher, H. Nückel, 2012, Indian Journal of Hematology and Blood Transfusion.

MTX-induced white matter changes are associated with polymorphisms of methionine metabolism

K. Fliessbach, H. Urbach, T. Klockgether, 2005, Neurology.

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

M. Kersten, D. Hose, H. Goldschmidt, 2013 .

Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.

H. Urbach, A. Glasmacher, U. Schlegel, 2009, Neuro-oncology.

Real-Time High-Resolution Compound Imaging Allows Percutaneous Initiation and Surveillance in an Orthotopic Murine Pancreatic Cancer Model

T. Sauerbruch, V. Schmitz, C. Ziske, 2008, Pancreas.

Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study.

A. Krämer, A. Ho, A. Benner, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total ascitic fluid leukocyte count for reliable exclusion of spontaneous bacterial peritonitis in patients with ascites

T. Sauerbruch, C. Ziske, I. Schmidt-Wolf, 2006, European journal of gastroenterology & hepatology.

High Survival Rate in Adult Burkitt’s Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma with Mediastinal Involvement.

W. Hiddemann, H. Döhner, M. Hansmann, 2007 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial

A. Glasmacher, C. Ziske, I. Schmidt-Wolf, 2003, Anti-cancer drugs.

Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells.

T. Sauerbruch, A. Glasmacher, I. Schmidt-Wolf, 2001, Haematologica.

Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12

Oliver Ebert, D. Huhn, I. Schmidt-Wolf, 1998, Cancer Immunology, Immunotherapy.

Cross-sectional increase of adherence to multidisciplinary tumor board decisions

I. Schmidt-Wolf, N. Ernstmann, M. Neumann, 2018, BMC Cancer.

Letter to the editor

Y. Ko, T. Klockgether, U. Schlegel, 2004 .

C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.

Y. Ko, T. Klockgether, U. Schlegel, 2004, Multiple sclerosis.

deletion 17p transplantation improves outcome in multiple myeloma patients with Administration of bortezomib before and after autologous stem cell

D. Hose, H. Goldschmidt, A. Jauch, 2012 .

Cyclophosphamide‐based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

H. Goldschmidt, A. Ho, I. Schmidt-Wolf, 2017, European journal of haematology.

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

Vindesine and etoposide: A practical and well-tolerated therapy for elderly patients or patients in reduced clinical condition with extensive-stage small-cell lung cancer (SCLC).

A. Glasmacher, I. Schmidt-Wolf, F. Risse, 2005, Medical science monitor : international medical journal of experimental and clinical research.

Characterization of the Karyotype in Patients with Multiple Myeloma by the Combination of Karyotype Analysis, FISH and CGH

I. Schmidt-Wolf, G. Schwanitz, U. Gamerdinger, 2010 .

Severe Abdominal Infections in Neutropenic Patients

C. Leutner, T. Sauerbruch, A. Glasmacher, 2001, Cancer investigation.

Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.

T. Sauerbruch, U. Spengler, I. Schmidt-Wolf, 2000, Cytokine.

Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.

P. Albers, I. Schmidt-Wolf, A. Märten, 2004, The Journal of urology.

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole

C. Leutner, E. Wardelmann, T. Sauerbruch, 1999, Mycoses.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

H. Oettle, I. Schmidt-Wolf, K. Ridwelski, 2007 .

Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

E. Thiel, W. Hiddemann, H. Döhner, 2012 .

Propagation of large numbers of T cells with natural killer cell markers

D. Huhn, I. Schmidt-Wolf, R. Negrin, 1994, British journal of haematology.

Novel non-viral method for transfection of primary leukemia cells and cell lines

I. Schmidt-Wolf, F. Schakowski, P. Buttgereit, 2004 .

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

T. Sauerbruch, A. Glasmacher, C. Ziske, 2003, British Journal of Cancer.

Results with a modified human myeloma stem cell assay

I. Schmidt-Wolf, O. Wetter, C. Hertenstein, 1983, Klinische Wochenschrift.

Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias

K. Döhner, R. Schlenk, H. Döhner, 2011 .

Clostridium difficile infection in patients with neutropenia.

T. Sauerbruch, A. Glasmacher, C. Ziske, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia

C. Leutner, E. Wardelmann, T. Sauerbruch, 1998, Leukemia.

Evaluation of an ultrasound-guided technique for central venous access via the internal jugular vein in 493 patients

T. Sauerbruch, A. Glasmacher, C. Ziske, 2003, Supportive Care in Cancer.

Acute transient encephalopathy after paclitaxel infusion: report of three cases.

T. Sauerbruch, U. Schlegel, C. Ziske, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients.

A. Glasmacher, I. Schmidt-Wolf, S. Schulte, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison

T. Sauerbruch, A. Glasmacher, C. Ziske, 2003, Supportive Care in Cancer.

Prestimulation of monocytes by the cytokines GM-CSF or IL- 2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A1

U. Spengler, I. Schmidt-Wolf, D. Flieger, 2000, Zeitschrift fur Gastroenterologie.